Advertisement

Neurosurgical Review

, Volume 8, Issue 3–4, pp 135–140 | Cite as

Role of cell and explant culture in the diagnosis and characterization of human pituitary tumours

  • Eric F. Adams
  • Keith Mashiter
Trends in pituitary surgery

Summary

The pattern of hormone secretion by human pituitary tumours in cell or explant culture has been shown to be of value in establishing the nature of the tissue. There was complete agreement between the diagnosis reached by conventional immunocytochemical techniques and by examining the secretion of hormones in culture. Culture techniques, however, have some advantages over immunocytochemical analysis. In particular, immunocytochemical techniques can only be used to examine a small, possibly unrepresentative, portion of the pituitary tissue, whereas the in vitro culture systems make use of the whole tissue. In addition, in vitro culture is simpler to employ and can be carried out relatively rapidly. Cell and explant culture was therefore used to examine the nature of human pituitary tumours.

To determine the incidence of mixed GH-PRL secreting pituitary tumours in acromegaly, the pattern of hormone secretion in vitro by 98 somatotrophic tumours was examined. Thirty-seven per cent were found to be pure somatotrophic tumours and 59.2% secreted both GH and PRL, but no other hormone, indicating that these tumours were of mixed nature. This latter group could be divided into those removed from patients with hyperprolactinaemia (35.7% of all tumours) and those from patients with normal pre-operative serum PRL levels (23.5%). A further small group (3.1%) of tumours secreted only GH in culture, despite elevated pre-operative serum PRL levels, indicating that the hyperprolactinaemia in these patients was due to pituitary stalk compression by the somatotrophic tumour, thereby preventing prolactin release inhibiting factor reaching the lactotrophs and allowing uncontrolled PRL secretion.

Pituitary tumours, pre-operatively diagnosed as ‘functionless’ could be classified on a secretory basis, most producing gonadotrophins (57.3%), whilst 7.3% secreted GH, 8.5% secreted PRL and 1.2% secreted ACTH. Presence or absence of PRL secretion by ‘functionless’ tumours was correlated with 88 patients whose pre-operative serum PRL was measured. The findings indicated that, in this series, 12.7% of tumours diagnosed as ‘functionless’ were, in fact, prolactinomas. Additionally, 18.3% of ‘functionless’ tumours failed to secrete PRL in vitro but were removed from patients with elevated PRL levels. These results suggest that the pre-operative hyperprolactinaemia in these cases was due to compression of the pituitary stalk by the tumour. It is concluded that in vitro pituitary culture techniques can be used to diagnose and characterize the nature of pituitary tumours.

Keywords

Diagnosis hormone secretion in vitro culture pituitary tumours 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Adams, E. F., I. E. Brajkovich, K. Mashiter: Growth hormone and prolactin secretion by dispersed cell cultures of human pituitary adenomas: long term effects of hydrocortisone, estradiol, insulin, 3,5,3′-triiodothyronine and thyroxine. J. Clin. Endocrinol. Metab. 53 (1981) 381–386PubMedGoogle Scholar
  2. [2]
    Adams, E. F., S. C. Bhuttacharji, C. L. J. Halliwell, M. Loizou, G. Birch, K. Mashiter: Effect of pancreatic growth hormone releasing factors on GH secretion by human somatotrophic pituitary tumours in cell culture. Clin. Endocrinol. (Oxf) 21 (1984) 709–718Google Scholar
  3. [3]
    De Pablo, F., R. C. Eastman, J. Roth, P. Gordon: Plasma prolactin in acromegaly before and after treatment. J. Clin. Endocrinol. Metab. 53 (1981) 344–352PubMedGoogle Scholar
  4. [4]
    Esiri, M. M., C. B. T. Adams, C. Burke, R. Underdown: Pituitary adenomas: immunohistology and ultrastructural analysis of 118 tumours. Acta Neuropathol. (Berl) 62 (1983) 1–14Google Scholar
  5. [5]
    Franks, S., H. S. Jacobs, J. D. N. Nabarro: Prolactin concentrations in patients with acromegaly: clinical significance and response to surgery. Clin. Endocrinol. (Oxf) 5 (1976) 63–69Google Scholar
  6. [6]
    Frantz, A. G., D. L. Kleinberg, G. L. Noel: Prolactin studies in man. Recent. Prog. Horm. Res. 28 (1972) 527–589PubMedGoogle Scholar
  7. [7]
    Fukaya, T., N. Kageyama, A. Kuwayama, M. Takanohashi, C. Okada, J. Yoshida, Y. Osamura: Morphofunctional study of pituitary adenomas with acromegaly by immunoperoxidase technique and electron microscopy. Cancer 45 (1980) 1598–1603PubMedGoogle Scholar
  8. [8]
    Gwee, H. M., K. Mashiter: A 24 hour radioimmunoassay for human prolactin. J. Endocrinol. 50 (1978) 566–567Google Scholar
  9. [9]
    Hall, R., J. Anderson, G. A. Smart, M. Besser: Fundamentals of Clinical Endocrinology. Pitman Medical, London 1980Google Scholar
  10. [10]
    Horvath, E., K. Kovacs, D. W. Killinger, H. S. Smyth, M. E. Platts, W. Singer: Silent corticotrophic adenomas of the human pituitary gland: a histologic, immunocytologic and ultrastructural study. Am. J. Pathol. 98 (1980) 617–638PubMedGoogle Scholar
  11. [11]
    Klijn, J. G. M., S. W. J. Lamberts, F. H. De Jong, K. J. Vandongen, J. C. Birkenhager: Interrelationships between tumour size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinol. (Copenh) 95 (1980) 289–297Google Scholar
  12. [12]
    Kovacs, K., E. Horvath, T. Baylay, S. T. Hassaram, C. Ezrin: Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. Am. J. Med. 64 (1978) 492–499PubMedGoogle Scholar
  13. [13]
    Kuku, S. F., P. Haroulis, J. L. Young, T. R. Fraser: Concentrations of immunoreactive thyrotropin hormone in urine of normal subjects, patients with thyroid disorders, and hypopituitarism and after infusion of human thyrotrophic hormone. J. Endocrinol. 62 (1974) 645–655PubMedGoogle Scholar
  14. [14]
    Marshall, J. C., D. C. Anderson, C. W. Burke, A. Galvao-Teles, T. R. Fraser: Clomiphene citrate in man: increase of cortisol. luteinizing hormone, testosterone and steroid binding globulins. J. Endocrinol. 53 (1972) 261–276PubMedGoogle Scholar
  15. [15]
    Marshall, J., D. C. Anderson, T. R. Fraser, P. Harsoulis: Human luteinizing hormone in man: studies of metabolism and biological action. J. Endocrinol. 56 (1973) 431–439PubMedGoogle Scholar
  16. [16]
    Mashiter, K., S. Van Noorden, L. De Marco, E. Adams, G. F. Joplin: Hormone secretion by human somatotrophic, lactotrophic, and mixed pituitary adenomas in culture. J. Clin. Endocrinol. Metab. 48 (1979) 108–113PubMedGoogle Scholar
  17. [17]
    Mashiter, K., E. Adams, S. Van Noorden: Secretion of LH, FSH and PRL shown by cell culture and immunohistochemistry of human “functionless” pituitary adenomas. Clin. Endocrinol. (Oxf) 15 (1981) 103–112Google Scholar
  18. [18]
    Mashiter, K., S. Van Noorden, R. Fahlbusch, H. Fill, K. Skrabal: Hyperthyroidism due to a TSH secreting pituitary adenoma: case report, treatment and evidence for adenoma TSH by morphological and cell culture studies. Clin. Endocrinol. (Oxf) 18 (1984) 473–483Google Scholar
  19. [19]
    McCormick, W. F., N. S. Halmi: Absence of chromophobe adenomas from a large series of pituitary tumors. Arch. Pathol. 92 (1971) 231–238PubMedGoogle Scholar
  20. [20]
    Trouillas, J., C. Girod, G. Sassolas, B. Claustrat, M. Lhéritier, M. P. Dubois: Human pituitary gonadotrophic adenomas: histological, immunocytochemical and ultrastructural and hormonal studies in eight cases. J. Pathol. 135 (1981) 315–336PubMedGoogle Scholar

Copyright information

© Walter de Gruyter & Co. 1985

Authors and Affiliations

  • Eric F. Adams
    • 1
    • 2
  • Keith Mashiter
    • 1
    • 3
  1. 1.Royal Postgraduate Medical SchoolUniversity of LondonUK
  2. 2.Endocrine Unit Department of Medicine Royal Postgraduate Medical SchoolHammersmith HospitalLondonUK
  3. 3.Clinical Reagents Research and DevelopmentAmersham International Plc.AmershamUK

Personalised recommendations